1. Pink Sheet
  2. >>Product Reviews
  3. >>Complete Response Letters

Quality Issues Star In US FDA Complete Response Letter Trio

 
• By Bridget Silverman

Rocket Pharmaceuticals’ gene therapy Kresladi, Daiichi Sankyo/Merck’s patritumab deruxtecan, and AbbVie’s foscarbidopa/foslevodopa (ABBV-951) received CRLs because of manufacturing concerns.

drug manufacturing
Three FDA CRLs disclosed this week included manufacturing problems. • Source: Shutterstock

In an unusual move, three US Food and Drug Administration complete response letters related to manufacturing issues were announced in the same week, all relating to very different products: a gene therapy, an antibody-drug conjugate (ADC), and a prodrug/device combination.

Key Takeaways

  • Rocket Pharmaceuticals stressed the limited scope of the Kresladi CRL and its alignment with senior CBER staff.

The CRL for Rocket Pharmaceuticals Inc.’s lentiviral vector-based gene therapy Kresladi (marnetegragene autotemcel) requests “limited additional chemistry manufacturing and...

More from Complete Response Letters

More from Product Reviews

Kisunla Back In The Spotlight As EMA Reconsiders Alzheimer’s Drug Rejection

 
• By Eliza Slawther

It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.

Post-Approval, Real-Time Monitoring Will Help Approval Standards, US FDA’s Makary Says

 
• By Sue Sutter

The FDA will use electronic health records to “get eyes” on drugs immediately after approval, Commissioner Martin Makary told the DIA 2025 Global Annual Meeting. He also wants to reduce development time with better communication and new approval pathways.

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.